Bayer HealthCare / U.S. FDA Approves Xarelto® (Rivaroxaban) to Treat Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) as well as to Reduce the Risk of Recurrent Events

News Details

Please confirm that you are a medical journalist.
This website is intended to provide information to an international audience outside the USA and UK. Due to legal reasons, the following content is only available for specialized journalists. To access these pages, please confirm that you are a medical journalist and that you would like to accredit to the Bayer HealthCare press portal.

Bayer HealthCare Links

Newsroom
Researchers discuss colored molecule structure of rivaroxaban

http://press.healthcare.bayer.com/en/press/news-details-page.php/14798/2012-0469

Copyright © Bayer HealthCare AG